The Historical Relationship Between Meis1 and Leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute leukemia (AL) is a complex hematological malignancy characterized by distinct subtypes and immunophenotypic properties.
• Leukemia stem cells (LSCs), derived from malignant transformation of hematopoietic progenitor and stem cells (HPSCs), are crucial for AL prognosis, endurance, and relapse due to self-renewal and chemotherapy resistance.
• The myeloid ecotropic integration site-1 (MEIS1) protein, a homeodomain protein, is implicated in tumorigenesis and has been found to be overexpressed in AL patients.

Purpose of the Study:

• To review the molecular mechanisms underlying the oncogenic role of the MEIS1 protein in leukemia and LSCs.
• To explore the potential of MEIS1 as a therapeutic target for leukemia treatment.

Main Methods:

• Literature review focusing on molecular mechanisms of MEIS1 in leukemia.
• Analysis of studies reporting MEIS1 expression in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients.
• Examination of the correlation between MEIS1 expression and chemotherapy resistance.

Main Results:

• Overexpression of MEIS1 transcript and protein is consistently observed in acute leukemia (AL) patients.
• High MEIS1 content in leukemic blasts correlates with resistance to conventional chemotherapy.
• MEIS1 plays a significant role in the oncogenesis and maintenance of leukemia stem cells (LSCs).

Conclusions:

• The MEIS1 protein is a key molecular driver in the development and progression of acute leukemia.
• MEIS1 overexpression in LSCs contributes to chemotherapy resistance and disease relapse.
• Targeting MEIS1, particularly its inhibition in overexpressing LSCs, presents a promising therapeutic strategy for leukemia treatment.